Tech Company Financing Transactions

DEM BioPharma Funding Round

On 6/23/2022, DEM BioPharma raised $70 million in investment from Alta Partners, Longwood Fund and Alexandria Venture Investments.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Proceeds Purpose
DEM Bio is focused on accessing the largely untapped opportunity around macrophage biology and innate immune system pathways to discover potent DEM and EM signals on cancers and expand the therapeutic potential of the field beyond the relatively small number of signals targeted by current investigational therapies.

Company Information

Company Status
Private & Independent
Mailing Address
lexandria LaunchLabs, One Kendall Square, Building 200, 001
Cambridge, MA 02139
Email Address
DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel 'don't eat me' (DEM) and 'eat me' (EM) signals on cancer cells and macrophages. Our proprietary CHoMP� platform (Co-culture with Human Myeloid Phagocytes) will be used to identify unexplored DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells. DEM Bio was co-founded by the Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik.
DEM BioPharma LinkedIn Company Profile
Social Media
DEM BioPharma Company Twitter Account
Company News
DEM BioPharma News
DEM BioPharma on Facebook
DEM BioPharma on YouTube

Management Team

Email & Social
Jan Skvarka
  Jan Skvarka LinkedIn Profile  Jan Skvarka Twitter Account  Jan Skvarka News  Jan Skvarka on Facebook
Chief Executive Officer
David Donabedian
  David Donabedian LinkedIn Profile  David Donabedian Twitter Account  David Donabedian News  David Donabedian on Facebook
Chief Operating Officer
John McCabe
  John McCabe LinkedIn Profile  John McCabe Twitter Account  John McCabe News  John McCabe on Facebook
John Pribis
  John Pribis LinkedIn Profile  John Pribis Twitter Account  John Pribis News  John Pribis on Facebook
Annie Vemu
  Annie Vemu LinkedIn Profile  Annie Vemu Twitter Account  Annie Vemu News  Annie Vemu on Facebook



Browse more venture capital transactions:

Prev: 6/23/2022: SumUp venture capital transaction
Next: 6/23/2022: BotsAndUs venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are derived from publicly available VC deal announcements. The information is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary